

**Middle East & Africa Human Vaccine Market Research Report Information by Vaccine Type (Inactivated, Toxoid, Conjugate and Subunit, Recombinant DNA), by Age Group (Pediatrics, and Adults), by Indication (Pneumococcal, Influenza, Hepatitis, DTP, Polio and others), by Route of Administration (Injectable, Oral, and others), by Distribution Channel (Public, and Private) Forecast to 2032**

Market Report | 2025-02-14 | 174 pages | Market Research Future

**AVAILABLE LICENSES:**

- Single User Price \$2950.00
- Enterprisewide Price \$5250.00

**Report description:**

Middle East & Africa Human Vaccine Market Research Report Information by Vaccine Type (Inactivated, Toxoid, Conjugate and Subunit, Recombinant DNA), by Age Group (Pediatrics, and Adults), by Indication (Pneumococcal, Influenza, Hepatitis, DTP, Polio and others), by Route of Administration (Injectable, Oral, and others), by Distribution Channel (Public, and Private) Forecast to 2032

**Overview of the Market**

During the review period, the human vaccine market in the Middle East and Africa is expected to grow at a compound annual growth rate (CAGR) of 8.80%. Human vaccinations are biological preparations that protect people from illness and its potentially serious effects by inducing immunity to a particular disease in the immune system. To elicit an immune response without actually causing the disease, these vaccines usually contain pathogens (such bacteria or viruses), their toxins, or surface proteins that have been weakened or destroyed.

The market for human vaccines in the Middle East and Africa is expanding due to rising disease burden, epidemic outbreaks, and growing knowledge of the value of vaccination in avoiding infectious illnesses. Furthermore, the industry will have future growth prospects due to the growing finance and investment for expansion.

**Market Segment Insights**

The human vaccination market in the Middle East and Africa has been divided into four segments based on the kind of vaccine:

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

inactivated, toxoid, conjugate and subunit, and recombinant DNA.

The human vaccine market in the Middle East and Africa has been divided into two age groups: adults and pediatrics. Throughout the projected period, the pediatrics sector grew at the highest rate and held the largest market in 2023.

The human vaccine market in the Middle East and Africa has been divided into segments based on indications, including polio, DTP, hepatitis, influenza, and pneumococcal.

The human vaccine market in the Middle East and Africa has been divided into injectable, oral, and other segments based on the route of administration.

The human vaccine market in the Middle East and Africa has been divided into two segments based on the distribution channel: public and private.

The market for human vaccines in the Middle East, which is further divided into the United Arab Emirates, Saudi Arabia, Israel, Kuwait, Oman, Qatar, Egypt, Bahrain, and the Rest of the Middle East, was worth USD Egypt million in 2023.

The market for human vaccines in the Middle East is expected to increase significantly due to rising healthcare costs, growing government backing for the vaccine, and growing awareness of its significance. The Kingdom of Saudi Arabia committed to funding the Global Polio Eradication Initiative (GPEI) with \$500 million over five years in April 2024. The launch of novel vaccinations that target a wider variety of diseases and improvements in vaccine technology further support the market's growth. To fight newly developing infectious diseases, current trends point to a move toward customized vaccinations and higher spending on research and development.

#### Key Players

Pfizer Inc., Merck & Co., Inc., AstraZeneca, Bharat Biotech, SaudiVax, Biovac, Vacsera, Cipla, GSK Plc, and Sanofi are the major companies in the Middle East human vaccine market.

## Table of Contents:

### TABLE OF CONTENTS

|       |  |    |
|-------|--|----|
| 1     | EXECUTIVE SUMMARY                                | 20 |
| 2     | MARKET INTRODUCTION                              | 22 |
| 2.1   | DEFINITION                                       | 22 |
| 2.2   | SCOPE OF THE STUDY                               | 22 |
| 2.3   | RESEARCH OBJECTIVE                               | 22 |
| 2.4   | MARKET STRUCTURE                                 | 23 |
| 3     | RESEARCH METHODOLOGY                             | 24 |
| 3.1   | OVERVIEW   | 24 |
| 3.2   | DATA FLOW  | 26 |
| 3.2.1 | DATA MINING PROCESS                              | 26 |
| 3.3   | PURCHASED DATABASE:                              | 27 |
| 3.4   | SECONDARY SOURCES:                               | 28 |
| 3.4.1 | SECONDARY RESEARCH DATA FLOW:                    | 29 |
| 3.5   | PRIMARY RESEARCH:                                | 30 |
| 3.5.1 | PRIMARY RESEARCH DATA FLOW:                      | 31 |
| 3.5.2 | PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED | 32 |
| 3.6   | APPROACHES FOR MARKET SIZE ESTIMATION:           | 32 |
| 3.6.1 | REVENUE ANALYSIS APPROACH                        | 32 |
| 3.7   | DATA FORECASTING                                 | 33 |
| 3.7.1 | DATA FORECASTING TYPE                            | 33 |
| 3.8   | DATA MODELING                                    | 34 |
| 3.8.1 | MICROECONOMIC FACTOR ANALYSIS:                   | 34 |
| 3.8.2 | DATA MODELING:                                   | 35 |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3.9 TEAMS AND ANALYST CONTRIBUTION 37
- 3.10 38
- 4 MARKET DYNAMICS 39
  - 4.1 INTRODUCTION 39
  - 4.2 DRIVERS 40
    - 4.2.1 INCREASING AWARENESS ABOUT THE IMPORTANCE OF VACCINATION IN PREVENTING INFECTIOUS DISEASES 40
    - 4.2.2 RISING DISEASE BURDEN AND EPIDEMIC OUTBREAKS 40
    - 4.2.3 RISING STRATEGIC INITIATIVES ASSOCIATED WITH VACCINE IN MIDDLE EAST & AFRICA 40
  - 4.3 RESTRAINTS 41
    - 4.3.1 STRINGENT REGULATORY POLICIES 41
  - 4.4 OPPORTUNITY 43
    - 4.4.1 INCREASING FUNDING AND INVESTMENT FOR EXPANSION 43
- 5 MARKET FACTOR ANALYSIS 44
  - 5.1 PORTER'S FIVE FORCES MODEL 44
    - 5.1.1 THREAT OF NEW ENTRANTS 45
    - 5.1.2 BARGAINING POWER OF SUPPLIERS 45
    - 5.1.3 BARGAINING POWER OF BUYERS 45
    - 5.1.4 THREAT OF SUBSTITUTES 45
    - 5.1.5 INTENSITY OF RIVALRY 45
  - 5.2 IMPACT OF COVID-19 ON THE MIDDLE EAST & AFRICA HUMAN VACCINES MARKET 46
- 6 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY VACCINE TYPE 48
  - 6.1 OVERVIEW 48
  - 6.2 INACTIVATED 50
  - 6.3 TOXOID 51
  - 6.4 CONJUGATE AND SUBUNIT 51
  - 6.5 RECOMBINANT DNA 51
- 7 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY AGE GROUP 52
  - 7.1 OVERVIEW 52
  - 7.2 PEDIATRICS 54
  - 7.3 ADULTS 54
- 8 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY INDICATION 55
  - 8.1 OVERVIEW 55
  - 8.2 PNEUMOCOCCAL 58
    - 8.3 INFLUENZA 58
    - 8.4 HEPATITIS 58
      - 8.4.1 HEPATITIS A 59
      - 8.4.2 HEPATITIS B 60
  - 8.5 DTP 60
  - 8.6 POLIO 61
    - 8.6.1 INACTIVATED POLIO VACCINE (IPV) 62
    - 8.6.2 ORAL POLIO VACCINE (OPV) 62
  - 8.7 HUMAN PAPILLOMAVIRUS 62
  - 8.8 MENINGOCOCCAL 63
- 9 MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY ROUTE OF ADMINISTRATION 64
  - 9.1 OVERVIEW 64
  - 9.2 INJECTABLE 67
  - 9.3 ORAL 67

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

|        |  |     |
|--------|--|-----|
| 9.4    | OTHERS   | 67  |
| 10     | MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY DISTRIBUTION CHANNEL | 68  |
| 10.1   | OVERVIEW   | 68  |
| 10.2   | PUBLIC   | 70  |
| 10.3   | PRIVATE  | 70  |
| 11     | MIDDLE EAST & AFRICA HUMAN VACCINE MARKET, BY REGION               | 71  |
| 11.1   | MIDDLE EAST  | 72  |
| 11.1.1 | UAE  | 79  |
| 11.1.2 | SAUDI ARABIA   | 83  |
| 11.1.3 | ISRAEL   | 87  |
| 11.1.4 | KUWAIT   | 91  |
| 11.1.5 | OMAN   | 96  |
| 11.1.6 | QATAR  | 99  |
| 11.1.7 | EGYPT  | 102 |
| 11.1.8 | BAHRAIN  | 106 |
| 11.1.9 | REST OF MIDDLE EAST  | 109 |
| 11.2   | AFRICA   | 113 |
| 11.2.1 | KENYA  | 119 |
| 11.2.2 | SOUTH AFRICA   | 122 |
| 11.2.3 | NIGERIA  | 126 |
| 11.2.4 | MOZAMBIQUE   | 129 |
| 11.2.5 | TANZANIA   | 132 |
| 11.2.6 | UGANDA   | 136 |
| 11.2.7 | MOROCCO  | 139 |
| 11.2.8 | REST OF AFRICA   | 143 |
| 12     | COMPETITIVE LANDSCAPE  | 148 |
| 12.1   | INTRODUCTION   | 148 |
| 12.2   | MARKET SHARE ANALYSIS, 2023 (%)                                    | 148 |
| 12.3   | COMPETITOR DASHBOARD   | 149 |
| 12.4   | PUBLIC PLAYERS STOCK SUMMARY                                       | 150 |
| 12.5   | COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL                        | 150 |
| 12.6   | KEY DEVELOPMENTS & GROWTH STRATEGIES                               | 151 |
| 12.6.1 | PRODUCT LAUNCH/PRODUCT APPROVAL                                    | 151 |
| 12.6.2 | AGREEMENT/COLLABORATION/PARTNERSHIP                                | 151 |
| 13     | COMPANY PROFILES   | 152 |
| 13.1   | SANOFI   | 152 |
| 13.1.1 | COMPANY OVERVIEW   | 152 |
| 13.1.2 | FINANCIAL OVERVIEW   | 153 |
| 13.1.3 | PRODUCTS OFFERED   | 153 |
| 13.1.4 | KEY DEVELOPMENTS   | 154 |
| 13.1.5 | SWOT ANALYSIS  | 155 |
| 13.1.6 | KEY STRATEGIES   | 155 |
| 13.2   | BHARAT BIOTECH   | 156 |
| 13.2.1 | COMPANY OVERVIEW   | 156 |
| 13.2.2 | FINANCIAL OVERVIEW   | 157 |
| 13.2.3 | PRODUCTS OFFERED   | 157 |
| 13.2.4 | KEY DEVELOPMENTS   | 157 |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

|        |                    |     |
|--------|--------------------|-----|
| 13.2.5 | KEY STRATEGIES     | 157 |
| 13.3   | PFIZER INC         | 158 |
| 13.3.1 | COMPANY OVERVIEW   | 158 |
| 13.3.2 | FINANCIAL OVERVIEW | 159 |
| 13.3.3 | PRODUCTS OFFERED   | 159 |
| 13.3.4 | KEY DEVELOPMENTS   | 160 |
| 13.3.5 | SWOT ANALYSIS      | 160 |
| 13.3.6 | KEY STRATEGIES     | 161 |
| 13.4   | MERCK & CO., INC.  | 162 |
| 13.4.1 | COMPANY OVERVIEW   | 162 |
| 13.4.2 | FINANCIAL OVERVIEW | 163 |
| 13.4.3 | PRODUCTS OFFERED   | 164 |
| 13.4.4 | KEY DEVELOPMENTS   | 164 |
| 13.4.5 | KEY STRATEGIES     | 164 |
| 13.5   | ASTRAZENECA        | 165 |
| 13.5.1 | COMPANY OVERVIEW   | 165 |
| 13.5.2 | FINANCIAL OVERVIEW | 166 |
| 13.5.3 | PRODUCTS OFFERED   | 166 |
| 13.5.4 | KEY DEVELOPMENTS   | 167 |
| 13.5.5 | KEY STRATEGIES     | 167 |
| 13.6   | CIPLA              | 168 |
| 13.6.1 | COMPANY OVERVIEW   | 168 |
| 13.6.2 | FINANCIAL OVERVIEW | 169 |
| 13.6.3 | PRODUCTS OFFERED   | 169 |
| 13.6.4 | KEY DEVELOPMENTS   | 169 |
| 13.6.5 | SWOT ANALYSIS      | 170 |
| 13.6.6 | KEY STRATEGIES     | 170 |
| 13.7   | SAUDIVAX           | 171 |
| 13.7.1 | COMPANY OVERVIEW   | 171 |
| 13.7.2 | FINANCIAL OVERVIEW | 172 |
| 13.7.3 | PRODUCTS OFFERED   | 172 |
| 13.7.4 | KEY DEVELOPMENTS   | 172 |
| 13.7.5 | KEY STRATEGIES     | 172 |
| 13.8   | GSK PLC            | 173 |
| 13.8.1 | COMPANY OVERVIEW   | 173 |
| 13.8.2 | FINANCIAL OVERVIEW | 174 |
| 13.8.3 | PRODUCT OFFERED    | 175 |
| 13.8.4 | KEY DEVELOPMENTS   | 175 |
| 13.8.5 | SWOT ANALYSIS      | 176 |
| 13.8.6 | KEY STRATEGIES     | 176 |
| 13.9   | BIOVAC             | 177 |
| 13.9.1 | COMPANY OVERVIEW   | 177 |
| 13.9.2 | FINANCIAL OVERVIEW | 178 |
| 13.9.3 | PRODUCTS OFFERED   | 178 |
| 13.9.4 | KEY DEVELOPMENTS   | 178 |
| 13.9.5 | KEY STRATEGIES     | 178 |
| 13.10  | VACSERA            | 179 |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 13.10.1 COMPANY OVERVIEW 179
- 13.10.2 FINANCIAL OVERVIEW 179
- 13.10.3 PRODUCTS OFFERED 179
- 13.10.4 KEY DEVELOPMENTS 180
- 13.10.5 KEY STRATEGIES 180
- 14 DATA CITATIONS 181

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Middle East & Africa Human Vaccine Market Research Report Information by Vaccine Type (Inactivated, Toxoid, Conjugate and Subunit, Recombinant DNA), by Age Group (Pediatrics, and Adults), by Indication (Pneumococcal, Influenza, Hepatitis, DTP, Polio and others), by Route of Administration (Injectable, Oral, and others), by Distribution Channel (Public, and Private) Forecast to 2032**

Market Report | 2025-02-14 | 174 pages | Market Research Future

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

| Select license | License              | Price     |
|----------------|----------------------|-----------|
|                | Single User Price    | \$2950.00 |
|                | Enterprisewide Price | \$5250.00 |
|                |                      | VAT       |
|                |                      | Total     |

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

|               |                      |                               |                      |
|---------------|----------------------|-------------------------------|----------------------|
| Email*        | <input type="text"/> | Phone*                        | <input type="text"/> |
| First Name*   | <input type="text"/> | Last Name*                    | <input type="text"/> |
| Job title*    | <input type="text"/> |                               |                      |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/> |
| Address*      | <input type="text"/> | City*                         | <input type="text"/> |
| Zip Code*     | <input type="text"/> | Country*                      | <input type="text"/> |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-13

Signature

A large, empty rectangular box intended for a signature.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com